Sector News

Celladon halves its workforce to conserve cash after gene therapy meltdown

May 15, 2015
Life sciences
Reeling after the Phase IIb failure of its “breakthrough” gene therapy for heart failure, Celladon ($CLDN) is slashing its budget and payroll, vowing to find a way forward that preserves value for its investors.
 
Last month, the company disclosed that its top prospect, Mydicar, failed to reduce hospitalizations, improve cardio survival rates or free patients from the need for ventricular-assist devices and heart transplants, an across-the-board failure that decimated the company’s market value.
 
Now the San Diego biotech is scrimping to stay alive, reducing its 34-person staff by 50% this quarter in an effort to save cash. Celladon is also backing out of a pair of manufacturing agreements with Novasep and Lonza–no longer needed now that Mydicar isn’t headed for Phase III–and the company is walking away from a loan agreement under which it would have taken on $15 million in debt.
 
Celladon closed the quarter with $70.6 million in cash and equivalents, enough to keep the doors open as management evaluates its pipeline and looks into “strategic alternatives to maximize value for our stockholders,” the company said in a regulatory filing. The company has already nixed an ongoing Phase I trial testing Mydicar in conjunction with a heart device and is now weighing what to do with a preclinical stem cell program to treat heart attack and an early-stage small-molecule drug with the same target as Mydicar.
 
“We are in the process of conducting an extensive review of the (Mydicar) data in the attempt to better understand the observed negative outcome,” CEO Krisztina Zsebo said in a statement. “Meanwhile, we are conserving our cash resources and are assessing our other previously planned clinical trials and development programs. We are also evaluating our strategic options in order to determine the best path forward to maximize shareholder value.”
 
To Celladon’s credit, throughout the Mydicar debacle, management has been up front with the public, bucking a trend in biotech and declining to mine for positive results in its failed trial or spin the setback as a success.
 
By Damian Garde
 

Related News

February 21, 2021

Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work

Life sciences

Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.

February 21, 2021

Gilead lets local HIV community groups take the lead with $3M grant

Life sciences

The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.

February 21, 2021

Biotech company funds research project on diversity

Life sciences

In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.

Send this to a friend